1347 related articles for article (PubMed ID: 32122466)
1. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
2. Immune metabolism in PD-1 blockade-based cancer immunotherapy.
Kumar A; Chamoto K
Int Immunol; 2021 Jan; 33(1):17-26. PubMed ID: 32622347
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
[TBL] [Abstract][Full Text] [Related]
5. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
7. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
8. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
9. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.
Gutwillig A; Santana-Magal N; Farhat-Younis L; Rasoulouniriana D; Madi A; Luxenburg C; Cohen J; Padmanabhan K; Shomron N; Shapira G; Gleiberman A; Parikh R; Levy C; Feinmesser M; Hershkovitz D; Zemser-Werner V; Zlotnik O; Kroon S; Hardt WD; Debets R; Reticker-Flynn NE; Rider P; Carmi Y
Elife; 2022 Sep; 11():. PubMed ID: 36124553
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
11. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.
Chowdhury PS; Chamoto K; Honjo T
J Intern Med; 2018 Feb; 283(2):110-120. PubMed ID: 29071761
[TBL] [Abstract][Full Text] [Related]
13. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
[TBL] [Abstract][Full Text] [Related]
14. Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
Wildes TJ; Dyson KA; Francis C; Wummer B; Yang C; Yegorov O; Shin D; Grippin A; Dean BD; Abraham R; Pham C; Moore G; Kuizon C; Mitchell DA; Flores CT
Clin Cancer Res; 2020 Nov; 26(21):5689-5700. PubMed ID: 32788225
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
19. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
20. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
